Accelerate Diagnosti (AXDX) 15.02 $AXDX
Accelerate Diagnostics to Present at the 36th Annual Growth Stock Conference
GlobeNewswire - Tue Jun 07, 6:07PM CDT
Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, the company's president and chief executive officer, is scheduled to present to investors at the 36 Annual Growth Stock Conference hosted by William Blair & Company, L.L.C. on June 15, 2016 at 8:00 a.m. Central Time at the Four Seasons Hotel in Chicago, Illinois. The presentation will be accessible from the investor portal of the company's website at http://ir.axdx.com.
AXDX: 15.02 (+0.70)
MedTech Stocks Q1 Earnings Preview: AXDX, CFMS, SENS
Zacks Equity Research - Zacks Investment Research - Wed May 11, 6:31AM CDT
All the three stocks carry a Zacks Rank #3 along with an Earnings ESP of 0.00% which does not conclusively predict an earnings beat in Q1.
CFMS: 7.49 (-0.01), AXDX: 15.02 (+0.70), SENS: 3.79 (-0.05)
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
VSAR: 10.48 (-0.30), IBKR: 39.02 (-0.97), AXDX: 15.02 (+0.70), ONCE: 53.58 (+0.03), YRD: 15.17 (-0.60)
5 Stocks with Rising Analyst Coverage
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 3:54PM CDT
New or increased coverage on a stock is usually the result of huge investor focus on it.
VSAR: 10.48 (-0.30), IBKR: 39.02 (-0.97), AXDX: 15.02 (+0.70), ONCE: 53.58 (+0.03), YRD: 15.17 (-0.60)
Accelerate Diagnostics to Present Data at European Congress
Globe Newswire - Sun Apr 10, 3:07PM CDT
TUCSON, Ariz., April 10, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. ("Accelerate"
announced today it will present data related to the Accelerate Pheno(TM) system and Accelerate PhenoTest(TM) BC kit for positive blood cultures while attending the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. The Accelerate Pheno(TM) system and Accelerate PhenoTest(TM) BC kit were formerly the Accelerate ID/AST System and Blood Culture Assay Kit.
AXDX: 15.02 (+0.70)
What Awaits Akers Biosciences (AKER) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 8:10AM CDT
Akers Biosciences Inc (AKER) is expected to report fourth-quarter 2015 earnings results on Mar 30.
AMZN: 717.91 (-9.74), AXDX: 15.02 (+0.70), AKER: 2.00 (-0.08)
BUYINS.NET: FFKT, CNBKA, MSM, AMP, PB, AXDX, Expected to Trade Higher After Bullish Insider Trading
M2 - Thu Feb 04, 8:50AM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. Farmers Capital Bank Corp (NASDAQ:FFKT), CENTURY BANCORP, INC. (NASDAQ:CNBKA), MSC INDUSTRIAL DIRECT CO., INC. (NYSE:MSM), AMERIPRISE FINANCIAL, INC. (NYSE:AMP), Prosperity Bancshares Inc (NYSE
, (NASDAQ:AXDX) are all expected to go Higher as Buy signals have been generated by top insider trading patterns.
CNBKA: 41.85 (-0.68), AXDX: 15.02 (+0.70), MSM: 72.97 (-2.29), FFKT: 26.52 (-0.47), AMP: 99.55 (-1.12), PB: 52.89 (-0.94)
Global Medical Laboratory Services Strategies, Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kww8xj/medical) has announced the addition of the "Medical Laboratory Services Strategies, Trends and Forecasts 2016 to 2019 - Global Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Trends like: - changing demographics - emerging economies and global prosperity - biotechnology advances in genetics - pathogen evolution - climate change - globalization - automation Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Medical Laboratory Services Strategies, Trends and Forecasts 2015 to 2019 - Global Version provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of the Clinical Laboratory Companies Mentioned - 35 of the 100 Companies - 23andMe - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - ACM Medical Laboratory - ACT Genomics - Adaptive Biotechnologies - Adicon Clinical Laboratories, Inc. - Aegis Sciences - Agena Bioscience - Alere Inc - Amarantus - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Atossa Genetics - Aurora Diagnostics, LLC - Baylor College of Medicin - Biofortuna - Biomnis (France) - BioReference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caprion - CareDx - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Claritas Genomics - Claymon Biomnis Laboratories Ltd. - Clinical Reference Laboratory, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Cypher Genomics - Cytogenetics For more information visit http://www.researchandmarkets.com/research/kww8xj/medical
ATOS: 0.31 (-0.01), AXDX: 15.02 (+0.70), ALR: 42.78 (+0.10), ARDX: 8.23 (-0.43)
Global Molecular Diagnostics Market Size, Strategies and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/w2l7rl/molecular) has announced the addition of the "Molecular Diagnostics Global Market Size, Strategies and Forecasts 2016 to 2019 " report to their offering. A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations. Trends like: - personalized medicine - pharmacogenomics - pathogen evolution - next generation sequencing - emergence of new economies with large markets - greater understanding of the role of genetic material in Disease and Health Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Molecular Diagnostics Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary Companies Mentioned - 14M Genomics - 23andMe - Abbott Laboratories - Abcam - Accelerate Diagnostics - AltheaDx - Atossa Genetics - Baylor College of Medicin - Becton, Dickinson & Co. - BioReference Laboratories, Inc. - bioM?rieux - Caprion - Cepheid - Claritas Genomics - Cypher Genomics - Cytogenetics - Diagnovus - Enzo Biochem - Epic Sciences - Foundation Medicine - Genomic Health - Genomic Vision - Good Start Genetics - Google - Great Basin Scientific - Grifols - Glyconics - Hologic - Premaitha - QuantRx? Biomedical - Quidel - Qvella - Response Genetics - Roche Molecular Diagnostics - Rosetta For more information visit http://www.researchandmarkets.com/research/w2l7rl/molecular
ATOS: 0.31 (-0.01), ABT: 38.40 (-0.47), BDX: 169.29 (-0.94), GBSNU: 16.22 (-0.28), FMI: 18.91 (-1.17), ENZ: 5.99 (-0.11), AXDX: 15.02 (+0.70), CPHD: 28.27 (-0.60), HOLX: 34.14 (-0.81), GHDX: 26.18 (-0.02)
Accelerate Diagnostics to Present at the J.P. Morgan 34th Annual Healthcare Conference on January 12th
GlobeNewswire - Tue Jan 05, 3:15PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, President and Chief Executive Officer, is scheduled to present at the J.P. Morgan 34 Annual Healthcare Conference in San Francisco, CA on Tuesday, January 12 at 7:30 AM PST / 10:30 AM EST.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Dec 09, 9:47PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being sold by Accelerate Diagnostics. The gross proceeds to Accelerate Diagnostics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $95.0 million. The offering is expected to close on or about December 15, 2015, subject to customary closing conditions. In addition, Accelerate Diagnostics has granted the underwriters of the offering a 30-day option to purchase up to an additional 838,235 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Dec 08, 3:01PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced that it has commenced an underwritten public offering of $80 million of shares of its common stock. All of the shares are being offered by Accelerate Diagnostics. In addition, Accelerate Diagnostics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $12 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics Reports Positive Results From Pilot Study of Its Investigational ID/AST System and Blood Culture Assay Kit and Initiation of Trial to Support FDA Clearance
GlobeNewswire - Wed Dec 02, 4:30AM CST
Accelerate Diagnostics, Inc. announced positive findings from a multicenter pilot study to evaluate external performance of its ID/AST System and Blood Culture Assay Kit. Based on the results of the study, the company also announced the initiation of its clinical trial for submission to the U.S. Food and Drug Administration.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics to Present at the 27th Annual Piper Jaffray Healthcare Conference on December 2, 2015
GlobeNewswire - Tue Dec 01, 4:37PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Piper Jaffray Healthcare Conference in New York City, NY on Wednesday, December 2nd at 12:30 PM ET.
AXDX: 15.02 (+0.70)
Multiple Insiders of Accelerate Diagnostics, Inc. (AXDX)-NasdaqCM bought Shares of AXDX
M2 - Fri Nov 06, 8:17AM CST
Multiple Insiders of Accelerate Diagnostics, Inc. (AXDX)-NasdaqCM bought 52,837 shares of AXDX from the open market on 2015-11-05. The stock was up 4.38% after the InsiderCow.com report.
AXDX: 15.02 (+0.70)
The World Market for Molecular Diagnostics 2015
M2 - Mon Oct 19, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hm2bt7/the_world_market) has announced the addition of the "The World Market for Molecular Diagnostics, 6th Edition" report to their offering. Molecular tests are used in just about every facet of laboratory medicine: infectious diseases, inherited diseases, coagulation, transplant medicine, prenatal and postnatal screening and cancer. The World Market for Molecular Diagnostics, 6th Edition, provides authoritative and complete analysis of the molecular testing industry. In this report, exclusive market sizing and forecasts are provided for the following diagnostic segments: - Cancer Markers & PGx - Histology (In situ hybridization, HPV) - Microbiology/Virology (HAI; HIV; Hepatitis; GC/Chlamydia; Respiratory; Organism ID; Mycobacteria, TB; Others) - Blood Screening - Coagulation & PGx - Prenatal Testing - Inherited Diseases Testing - Tissue Typing - Organ Transplant Testing (HLA Typing) - Circulating Tumor Cells (CTCs) - Clinical Sequencing - Flow Cytometry The amount of activity over the last few years is short of phenomenal with a continuous stream of new platforms, tests and quality control materials for test standardization coming to market. There is intense competition but also opportunities for entrants in some areas. Comprehensive Coverage of the Molecular Diagnostics Industry Molecular diagnostics is one of the fastest growth segments in clinical diagnostics, and for the past five years there's been a considerable rate of growth in the number of assays introduced. Moreover, growth of this segment is fuelled by rising incidence of chronic disorders, an increasing geriatric population and adoption of personalized medicines. This report not only contains current market data for business planning, it goes beyond the numbers to fully assess what is going on in the market and why. Since the last edition of this report, a lot has changed, and a lot has stayed the same. As part of its coverage, the report includes the following: - Over 1,000 Pages of Detailed Market Coverage - Over 70 Tables and Figures Makes Market Analysis More Accessible - Current Market Size and Forecast 2014-2019 for Several Specific Molecular IVD Segments - Exome Sequencing, Metabolic Profiling, Hospital Acquired Infections, LDTs, Information Technology, - Status of China and Emerging Markets and Other Trends - Infectious Disease Molecular Sales by Disease - Over 190 Profiles of Molecular Diagnostic Competitors - Recent Mergers and Acquisitions - Revenues of Test Service Companies - Geographic Breakout of the Molecular Diagnostics Market by Region - Sample Preparation Trends - Breakout of Molecular Histology/Cytology Market - Mergers, Partnerships, Distribution Agreements in Molecular IVD Key Topics Covered: 1. Executive Summary 2. Introduction 3. Delivering Molecular Tests To The Clinic 4. Sequencing - How Far Can We Go? 5. Market Analysis: World Markets 6. The Market For Blood Markers In Cancer 7. The Market For Molecular Assays In Hematology: Cell-Based Molecular Tests 8. The Market For Molecular Assays In Coagulation 9. Histology And Cytology 10. Microbiology And Virology 11. The Market For Molecular Assays In Blood Transfusion Medicine 12. The Market For Molecular Assays In Organ Transplant Management 13. The Market For Molecular Assays In Prenatal And Newborn Screening 14. The Market For Molecular Assays For Inherited Diseases 15. Conclusions And Strategic Implications 16. Major Vendors And Companies To Watch 17. Company Profiles: The Top Tier 18. Company Profiles: Major Molecular Companies 19. Company Profiles: Participants 20. Company Profiles: Great Expectations 21. Company Profiles: Newcomers 22. Company Profiles: Test Service Providers 23. Company Profiles: Point Of Care Test Specialists 24. Company Profiles: Sample Preparation 25. Company Profiles: Information Technology Specialists 26. Company Profiles: Histopathology Specialists 27. Company Profiles: Microbiology Specialists 28. Company Profiles: Blood Bank Specialists 29. Company Profiles: Prenatal Test Service Providers 30. Company Profiles: Ctc & Liquid Biopsy Test Providers Companies Mentioned - Partial List - 23andMe - Abbott Diagnostics - Accelerate Diagnostics, Inc. - Adaptive Biotechnologies Corporation - Advaita Bioinformatics - Advanced Biological Laboratories, S.A. (ABL) - Advanced Cell Diagnostics (ACD) - AdvanDx, Inc. - Affymetrix Inc. - Agendia BV - Agilent Technologies - Alere Inc. - AltheaDx Diagnostics, Inc. - altona Diagnostics - Ambry Genetics - Amoy Diagnostics Co. Ltd. - Angle plc - Aperiomics - ApoCell, Inc. - Apple Inc. - Applied Spectral Imaging Inc. (ASI) - Ariosa Diagnostics, Inc. - ARUP Laboratories - Assurex Health - Asuragen Inc. - Athena Diagnostics - Atlas Genetics Ltd. - AutoGenomics Inc. For more information visit http://www.researchandmarkets.com/research/hm...rld_market
AGMX: (), AXDX: 15.02 (+0.70), A: 45.36 (-0.73), ALR: 42.78 (+0.10), AAPL: 98.83 (-0.82), AFFX: 14.01 (+0.02), ATHN: 132.04 (-1.86)
Accelerate Diagnostics to Present at the 35th Annual Canaccord Genuity Growth Conference on August 13, 2015
GlobeNewswire - Wed Aug 05, 4:30AM CDT
Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 13th at 8:00AM ET.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics Achieves CE-IVD Milestone for ID/AST System and ID/AST Blood Culture Assay
GlobeNewswire - Tue Jun 30, 10:58PM CDT
Accelerate Diagnostics, Inc., announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79 EC and CE Mark of the Accelerate ID/AST System and ID/AST Blood Culture Assay for in vitro diagnostic use. The Accelerate ID/AST System is a diagnostic platform providing rapid identification and antimicrobial susceptibility testing of serious infections.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics to Present at the 36th Annual Growth Stock Conference
GlobeNewswire - Tue Jun 07, 6:07PM CDT
Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, the company's president and chief executive officer, is scheduled to present to investors at the 36 Annual Growth Stock Conference hosted by William Blair & Company, L.L.C. on June 15, 2016 at 8:00 a.m. Central Time at the Four Seasons Hotel in Chicago, Illinois. The presentation will be accessible from the investor portal of the company's website at http://ir.axdx.com.
AXDX: 15.02 (+0.70)
MedTech Stocks Q1 Earnings Preview: AXDX, CFMS, SENS
Zacks Equity Research - Zacks Investment Research - Wed May 11, 6:31AM CDT
All the three stocks carry a Zacks Rank #3 along with an Earnings ESP of 0.00% which does not conclusively predict an earnings beat in Q1.
CFMS: 7.49 (-0.01), AXDX: 15.02 (+0.70), SENS: 3.79 (-0.05)
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Interactive Brokers Group, Yirendai, Spark Therapeutics, Versartis and Accelerate Diagnostics
VSAR: 10.48 (-0.30), IBKR: 39.02 (-0.97), AXDX: 15.02 (+0.70), ONCE: 53.58 (+0.03), YRD: 15.17 (-0.60)
5 Stocks with Rising Analyst Coverage
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 3:54PM CDT
New or increased coverage on a stock is usually the result of huge investor focus on it.
VSAR: 10.48 (-0.30), IBKR: 39.02 (-0.97), AXDX: 15.02 (+0.70), ONCE: 53.58 (+0.03), YRD: 15.17 (-0.60)
Accelerate Diagnostics to Present Data at European Congress
Globe Newswire - Sun Apr 10, 3:07PM CDT
TUCSON, Ariz., April 10, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. ("Accelerate"
announced today it will present data related to the Accelerate Pheno(TM) system and Accelerate PhenoTest(TM) BC kit for positive blood cultures while attending the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. The Accelerate Pheno(TM) system and Accelerate PhenoTest(TM) BC kit were formerly the Accelerate ID/AST System and Blood Culture Assay Kit. AXDX: 15.02 (+0.70)
What Awaits Akers Biosciences (AKER) in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 8:10AM CDT
Akers Biosciences Inc (AKER) is expected to report fourth-quarter 2015 earnings results on Mar 30.
AMZN: 717.91 (-9.74), AXDX: 15.02 (+0.70), AKER: 2.00 (-0.08)
BUYINS.NET: FFKT, CNBKA, MSM, AMP, PB, AXDX, Expected to Trade Higher After Bullish Insider Trading
M2 - Thu Feb 04, 8:50AM CST
BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Higher in the next 6 months. Farmers Capital Bank Corp (NASDAQ:FFKT), CENTURY BANCORP, INC. (NASDAQ:CNBKA), MSC INDUSTRIAL DIRECT CO., INC. (NYSE:MSM), AMERIPRISE FINANCIAL, INC. (NYSE:AMP), Prosperity Bancshares Inc (NYSE
, (NASDAQ:AXDX) are all expected to go Higher as Buy signals have been generated by top insider trading patterns. CNBKA: 41.85 (-0.68), AXDX: 15.02 (+0.70), MSM: 72.97 (-2.29), FFKT: 26.52 (-0.47), AMP: 99.55 (-1.12), PB: 52.89 (-0.94)
Global Medical Laboratory Services Strategies, Trends and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/kww8xj/medical) has announced the addition of the "Medical Laboratory Services Strategies, Trends and Forecasts 2016 to 2019 - Global Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Trends like: - changing demographics - emerging economies and global prosperity - biotechnology advances in genetics - pathogen evolution - climate change - globalization - automation Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Medical Laboratory Services Strategies, Trends and Forecasts 2015 to 2019 - Global Version provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of the Clinical Laboratory Companies Mentioned - 35 of the 100 Companies - 23andMe - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - ACM Medical Laboratory - ACT Genomics - Adaptive Biotechnologies - Adicon Clinical Laboratories, Inc. - Aegis Sciences - Agena Bioscience - Alere Inc - Amarantus - American Pathology Partners, Inc. - ARUP Laboratories, Inc. - Ascend Clinical, LLC - Atossa Genetics - Aurora Diagnostics, LLC - Baylor College of Medicin - Biofortuna - Biomnis (France) - BioReference Laboratories, Inc. - Bioscientia Institut fuer Medizinische Diagnostik GmbH - BP Lab - Caprion - CareDx - Caris Life Sciences, Inc. - Centrex Clinical Laboratories, Inc. - Clarient, Inc. - Claritas Genomics - Claymon Biomnis Laboratories Ltd. - Clinical Reference Laboratory, Inc. - Clongen Laboratories LLC - CompuNet Clinical Laboratories, LLC - Cypher Genomics - Cytogenetics For more information visit http://www.researchandmarkets.com/research/kww8xj/medical
ATOS: 0.31 (-0.01), AXDX: 15.02 (+0.70), ALR: 42.78 (+0.10), ARDX: 8.23 (-0.43)
Global Molecular Diagnostics Market Size, Strategies and Forecasts 2016 to 2019
M2 - Tue Jan 26, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/w2l7rl/molecular) has announced the addition of the "Molecular Diagnostics Global Market Size, Strategies and Forecasts 2016 to 2019 " report to their offering. A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations. Trends like: - personalized medicine - pharmacogenomics - pathogen evolution - next generation sequencing - emergence of new economies with large markets - greater understanding of the role of genetic material in Disease and Health Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Molecular Diagnostics Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary Companies Mentioned - 14M Genomics - 23andMe - Abbott Laboratories - Abcam - Accelerate Diagnostics - AltheaDx - Atossa Genetics - Baylor College of Medicin - Becton, Dickinson & Co. - BioReference Laboratories, Inc. - bioM?rieux - Caprion - Cepheid - Claritas Genomics - Cypher Genomics - Cytogenetics - Diagnovus - Enzo Biochem - Epic Sciences - Foundation Medicine - Genomic Health - Genomic Vision - Good Start Genetics - Google - Great Basin Scientific - Grifols - Glyconics - Hologic - Premaitha - QuantRx? Biomedical - Quidel - Qvella - Response Genetics - Roche Molecular Diagnostics - Rosetta For more information visit http://www.researchandmarkets.com/research/w2l7rl/molecular
ATOS: 0.31 (-0.01), ABT: 38.40 (-0.47), BDX: 169.29 (-0.94), GBSNU: 16.22 (-0.28), FMI: 18.91 (-1.17), ENZ: 5.99 (-0.11), AXDX: 15.02 (+0.70), CPHD: 28.27 (-0.60), HOLX: 34.14 (-0.81), GHDX: 26.18 (-0.02)
Accelerate Diagnostics to Present at the J.P. Morgan 34th Annual Healthcare Conference on January 12th
GlobeNewswire - Tue Jan 05, 3:15PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, President and Chief Executive Officer, is scheduled to present at the J.P. Morgan 34 Annual Healthcare Conference in San Francisco, CA on Tuesday, January 12 at 7:30 AM PST / 10:30 AM EST.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Dec 09, 9:47PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced the pricing of an underwritten public offering of 5,588,236 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being sold by Accelerate Diagnostics. The gross proceeds to Accelerate Diagnostics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $95.0 million. The offering is expected to close on or about December 15, 2015, subject to customary closing conditions. In addition, Accelerate Diagnostics has granted the underwriters of the offering a 30-day option to purchase up to an additional 838,235 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Dec 08, 3:01PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) today announced that it has commenced an underwritten public offering of $80 million of shares of its common stock. All of the shares are being offered by Accelerate Diagnostics. In addition, Accelerate Diagnostics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $12 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics Reports Positive Results From Pilot Study of Its Investigational ID/AST System and Blood Culture Assay Kit and Initiation of Trial to Support FDA Clearance
GlobeNewswire - Wed Dec 02, 4:30AM CST
Accelerate Diagnostics, Inc. announced positive findings from a multicenter pilot study to evaluate external performance of its ID/AST System and Blood Culture Assay Kit. Based on the results of the study, the company also announced the initiation of its clinical trial for submission to the U.S. Food and Drug Administration.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics to Present at the 27th Annual Piper Jaffray Healthcare Conference on December 2, 2015
GlobeNewswire - Tue Dec 01, 4:37PM CST
Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Piper Jaffray Healthcare Conference in New York City, NY on Wednesday, December 2nd at 12:30 PM ET.
AXDX: 15.02 (+0.70)
Multiple Insiders of Accelerate Diagnostics, Inc. (AXDX)-NasdaqCM bought Shares of AXDX
M2 - Fri Nov 06, 8:17AM CST
Multiple Insiders of Accelerate Diagnostics, Inc. (AXDX)-NasdaqCM bought 52,837 shares of AXDX from the open market on 2015-11-05. The stock was up 4.38% after the InsiderCow.com report.
AXDX: 15.02 (+0.70)
The World Market for Molecular Diagnostics 2015
M2 - Mon Oct 19, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hm2bt7/the_world_market) has announced the addition of the "The World Market for Molecular Diagnostics, 6th Edition" report to their offering. Molecular tests are used in just about every facet of laboratory medicine: infectious diseases, inherited diseases, coagulation, transplant medicine, prenatal and postnatal screening and cancer. The World Market for Molecular Diagnostics, 6th Edition, provides authoritative and complete analysis of the molecular testing industry. In this report, exclusive market sizing and forecasts are provided for the following diagnostic segments: - Cancer Markers & PGx - Histology (In situ hybridization, HPV) - Microbiology/Virology (HAI; HIV; Hepatitis; GC/Chlamydia; Respiratory; Organism ID; Mycobacteria, TB; Others) - Blood Screening - Coagulation & PGx - Prenatal Testing - Inherited Diseases Testing - Tissue Typing - Organ Transplant Testing (HLA Typing) - Circulating Tumor Cells (CTCs) - Clinical Sequencing - Flow Cytometry The amount of activity over the last few years is short of phenomenal with a continuous stream of new platforms, tests and quality control materials for test standardization coming to market. There is intense competition but also opportunities for entrants in some areas. Comprehensive Coverage of the Molecular Diagnostics Industry Molecular diagnostics is one of the fastest growth segments in clinical diagnostics, and for the past five years there's been a considerable rate of growth in the number of assays introduced. Moreover, growth of this segment is fuelled by rising incidence of chronic disorders, an increasing geriatric population and adoption of personalized medicines. This report not only contains current market data for business planning, it goes beyond the numbers to fully assess what is going on in the market and why. Since the last edition of this report, a lot has changed, and a lot has stayed the same. As part of its coverage, the report includes the following: - Over 1,000 Pages of Detailed Market Coverage - Over 70 Tables and Figures Makes Market Analysis More Accessible - Current Market Size and Forecast 2014-2019 for Several Specific Molecular IVD Segments - Exome Sequencing, Metabolic Profiling, Hospital Acquired Infections, LDTs, Information Technology, - Status of China and Emerging Markets and Other Trends - Infectious Disease Molecular Sales by Disease - Over 190 Profiles of Molecular Diagnostic Competitors - Recent Mergers and Acquisitions - Revenues of Test Service Companies - Geographic Breakout of the Molecular Diagnostics Market by Region - Sample Preparation Trends - Breakout of Molecular Histology/Cytology Market - Mergers, Partnerships, Distribution Agreements in Molecular IVD Key Topics Covered: 1. Executive Summary 2. Introduction 3. Delivering Molecular Tests To The Clinic 4. Sequencing - How Far Can We Go? 5. Market Analysis: World Markets 6. The Market For Blood Markers In Cancer 7. The Market For Molecular Assays In Hematology: Cell-Based Molecular Tests 8. The Market For Molecular Assays In Coagulation 9. Histology And Cytology 10. Microbiology And Virology 11. The Market For Molecular Assays In Blood Transfusion Medicine 12. The Market For Molecular Assays In Organ Transplant Management 13. The Market For Molecular Assays In Prenatal And Newborn Screening 14. The Market For Molecular Assays For Inherited Diseases 15. Conclusions And Strategic Implications 16. Major Vendors And Companies To Watch 17. Company Profiles: The Top Tier 18. Company Profiles: Major Molecular Companies 19. Company Profiles: Participants 20. Company Profiles: Great Expectations 21. Company Profiles: Newcomers 22. Company Profiles: Test Service Providers 23. Company Profiles: Point Of Care Test Specialists 24. Company Profiles: Sample Preparation 25. Company Profiles: Information Technology Specialists 26. Company Profiles: Histopathology Specialists 27. Company Profiles: Microbiology Specialists 28. Company Profiles: Blood Bank Specialists 29. Company Profiles: Prenatal Test Service Providers 30. Company Profiles: Ctc & Liquid Biopsy Test Providers Companies Mentioned - Partial List - 23andMe - Abbott Diagnostics - Accelerate Diagnostics, Inc. - Adaptive Biotechnologies Corporation - Advaita Bioinformatics - Advanced Biological Laboratories, S.A. (ABL) - Advanced Cell Diagnostics (ACD) - AdvanDx, Inc. - Affymetrix Inc. - Agendia BV - Agilent Technologies - Alere Inc. - AltheaDx Diagnostics, Inc. - altona Diagnostics - Ambry Genetics - Amoy Diagnostics Co. Ltd. - Angle plc - Aperiomics - ApoCell, Inc. - Apple Inc. - Applied Spectral Imaging Inc. (ASI) - Ariosa Diagnostics, Inc. - ARUP Laboratories - Assurex Health - Asuragen Inc. - Athena Diagnostics - Atlas Genetics Ltd. - AutoGenomics Inc. For more information visit http://www.researchandmarkets.com/research/hm...rld_market
AGMX: (), AXDX: 15.02 (+0.70), A: 45.36 (-0.73), ALR: 42.78 (+0.10), AAPL: 98.83 (-0.82), AFFX: 14.01 (+0.02), ATHN: 132.04 (-1.86)
Accelerate Diagnostics to Present at the 35th Annual Canaccord Genuity Growth Conference on August 13, 2015
GlobeNewswire - Wed Aug 05, 4:30AM CDT
Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, announced today that Lawrence Mehren, Chief Executive Officer, is scheduled to present a corporate update at the Canaccord Genuity Growth Conference in Boston, MA on Thursday, August 13th at 8:00AM ET.
AXDX: 15.02 (+0.70)
Accelerate Diagnostics Achieves CE-IVD Milestone for ID/AST System and ID/AST Blood Culture Assay
GlobeNewswire - Tue Jun 30, 10:58PM CDT
Accelerate Diagnostics, Inc., announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/79 EC and CE Mark of the Accelerate ID/AST System and ID/AST Blood Culture Assay for in vitro diagnostic use. The Accelerate ID/AST System is a diagnostic platform providing rapid identification and antimicrobial susceptibility testing of serious infections.
AXDX: 15.02 (+0.70)
